Contemporary Pediatrics, Digital Edition, January 2012

Roflumilast foam 0.3% trial investigator Jennifer Soung, MD, joined us to discuss the importance of this newly FDA-approved topical treatment for patients aged 12 years or older with scalp and body psoriasis.

“These findings provide evidence that social media may be contributing to the development of depressive symptoms,” said Jason M. Nagata, MD, MSc.

The expanded indication follows original approval in August 2018 for use in previously-treated patients 12 years and older.

These findings come as many health care professionals still report limited confidence and inconsistent practices regarding RSV immunization discussions.